Paul Tudor Jones Avidity Biosciences, Inc. Transaction History
Tudor Investment Corp Et Al
- $15.5 Billion
- Q1 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 68,887 shares of RNA stock, worth $2.67 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
68,887Holding current value
$2.67 Million% of portfolio
0.01%Shares
7 transactions
Others Institutions Holding RNA
# of Institutions
164Shares Held
71.6MCall Options Held
182KPut Options Held
55K-
Rtw Investments, LP New York, NY7.97MShares$309 Million3.26% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD7.43MShares$288 Million0.02% of portfolio
-
Black Rock Inc. New York, NY6.17MShares$239 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.83MShares$226 Million1.79% of portfolio
-
Cowen And Company, LLC5.63MShares$218 Million4.83% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $2.02B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...